Galapagos

What Galapagos does

Galapagos NV, founded in 1999 and headquartered in Mechelen, Belgium, operated as a clinical-stage biotechnology company for 27 years without ever securing a product approval. The company's pipeline focused on small-molecule and engineered cell therapies in autoimmune disease and oncology. Core clinical assets included GLPG3667, a selective TYK2 inhibitor in Phase II/III for dermatomyositis and systemic lupus erythematosus; gamgertamig (OM336), a BCMAxCD3 T-cell engager in Phase 1/2 for autoimmune hemolytic anemia and immune thrombocytopenia, carrying FDA Fast Track and Orphan Drug Designation; and GLPG5101, a CD19 CAR-T candidate with a 7-day vein-to-vein time. In May 2026 the company rebranded as Lakefront Biotherapeutics NV, pivoting from internal drug discovery toward an asset-acquisition and clinical-advancement model.

The company is monetizing primarily through a long-running strategic collaboration with Gilead Sciences (the largest shareholder at ~25%). Under the original 2019 OLCA agreement and the restructured March 2026 binding deal covering gamgertamig and the Ouro Medicines acquisition, Gilead retains worldwide commercialization rights and pays Galapagos 20–23% royalties on net sales. Galapagos co-funds 50% of upfront and milestone costs on co-developed programs, while the restructured deal freed up to $500M of Galapagos cash plus up to $150M for buybacks. The company ended FY2025 with approximately EUR 3 billion in cash and financial investments and reported collaboration revenue of EUR 1.11 billion, though this was largely a EUR 1,069M one-time release of deferred income from the OLCA agreement.

Following an October 2025 strategic review that concluded no viable offers were available, Galapagos wound down its cell therapy business, affecting roughly 365 employees across sites in the U.S., Netherlands, Switzerland, and China, and took an EUR 228M impairment. New leadership (CEO Henry Gosebruch, joined May 2026 from Neumora) is redirecting capital toward opportunistic business development in inflammation & immunology and oncology, supplemented by a EUR 50 million share repurchase program launched in June 2026. Commercialization of any approved assets is largely outsourced to Gilead, so the company's customer base in the foreseeable term is effectively one counterparty.

Name

Galapagos

Legal name

Lakefront Biotherapeutics NV

Website

https://glpg.com

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

251–500 employees

Short description

Galapagos (rebranded May 2026 as Lakefront Biotherapeutics NV) is a Belgium-based clinical-stage biotech that identifies, acquires, and advances clinical assets in autoimmune disease and oncology, monetizing through a Gilead Sciences partnership that grants worldwide commercialization rights in exchange for royalties.

Ownership category

akta.pro rank

Product category

Clinical-Stage Biopharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

akta.pro secondary industry

Lentiviral Vector Gene Therapy Developers (HLAAACAB)

Keywords

• Clinical-stage biotechnology
• Small molecule drug discovery
• Cell therapy development
• Autoimmune disease therapeutics
• Oncology drug development

Headquarters

HQ city

Mechelen-bovelingen

HQ country

Belgium

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Collaboration Revenue: Revenue from strategic partnership with Gilead Sciences, including upfront payments, milestone payments, and cost-sharing arrangements for co-development of autoimmune therapies
2. Royalties from Gilead Partnership: 20-23% royalties on net sales for programs developed under the collaboration, with Gilead retaining worldwide commercialization rights
3. Co-funding and Cost Sharing: Galapagos co-funds 50% of upfront and milestone payments for Ouro Medicines acquisition and development costs, with potential to unlock $500M cash and pursue independent research programs

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Galapagos (now operating as Lakefront Biotherapeutics) is a clinical-stage biotechnology company that identifies, acquires, and advances high-potential clinical-stage therapeutic assets in inflammation & immunology and oncology. The company develops small molecule medicines (TYK2 inhibitors, SIK3 inhibitors) and biologics (T-cell engagers, CAR T-cell therapies) for autoimmune diseases and hematological malignancies, monetizing its pipeline primarily through strategic co-development partnerships and licensing arrangements with major pharmaceutical companies such as Gilead Sciences.

Product overview

Galapagos NV is a Belgian biotech company that has been operating for 27 years without a product approval. The company underwent significant strategic transformation, including rebranding to Lakefront Biotherapeutics in May 2026. The core portfolio included: GLPG3667, a TYK2 inhibitor in late-stage clinical development for dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR T-cell therapy for mantle cell lymphoma (now discontinued); Gamgertamig (OM336), a BCMAxCD3 T-cell engager partnered with Gilead for autoimmune diseases; and COL-5671, a SIK3 inhibitor that was transferred to Coultreon Biopharma. The company wound down its cell therapy business in late 2025 and is pursuing new business development opportunities in inflammation & immunology and oncology.

Differentiator

Problem solved

Functional benefit

Products and services

• GLPG3667
• Gamgertamig (OM336)
• GLPG5101

Quantifiable outcome

• EUR 295.1 million operating profit in FY2025
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Gilead SciencescoreStrategic or Co-development Partner · 31 March 2026Strategic collaboration on developing gamgertamig (OM336), a first-in-class T-cell engager for autoimmune diseases. Galapagos co-funds 50% of upfront and milestone costs ($1.675B + up to $500M) and shares development costs equally, while Gilead retains worldwide commercialization rights and pays Galapagos 20-23% royalties on net sales. Deal also frees up to $500M of Galapagos cash for independent research and up to $150M for share repurchases.
• Coultreon BiopharmaminorStrategic or Co-development Partner · 1 April 2025Galapagos transferred COL-5671, an oral SIK3 inhibitor for autoimmune diseases, to Coultreon Biopharma in April 2025. Galapagos also provided initial seed investment in Coultreon and participated as investor in $125M Series A funding round.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• argenx: argenx is a clinical-to-commercial immunology biotech focused on autoimmune diseases with FcRn antagonists and other biologics, and is the most direct comparable to Lakefront in autoimmune T-cell engagers and bispecifics. Both companies pursue differentiated immunology assets with global partnerships and similar European origins.
• Vertex Pharmaceuticals: Vertex is a clinical-to-commercial biotech with a strong balance sheet pursuing transformative BD and internal R&D in specialty therapeutics, including immunology; its dealmaking-led growth model and cash-rich profile closely mirror Lakefront's repositioned strategy.
• Regeneron: Regeneron combines small molecule and biologics development across ophthalmology, immunology and oncology with a heavy emphasis on bispecific antibodies (e.g., linvoseltamab, odronextamab); its Regeneron Ventures arm also participated in the Coultreon Series A alongside Lakefront.
• Neumora Therapeutics: Neumora is a clinical-stage neuroscience biotech from which new Lakefront CEO Henry Gosebruch joined; both are relatively recent public biotechs pursuing a BD-enabled pipeline strategy in specialty therapeutics.

Broad incumbents

• Gilead Sciences: Gilead is Lakefront's largest shareholder (~25%) and worldwide commercialization partner on gamgertamig, with a broader oncology and antiviral portfolio that includes CAR-T franchises (Yescarta, Tecartus) overlapping with Lakefront's discontinued cell therapy work.
• AbbVie: AbbVie is a global immunology leader (Humira, Skyrizi, Rinvoq) operating in many of the same autoimmune disease areas Lakefront targets, including dermatomyositis and SLE; Fred Blakeslee previously led legal M&A at AbbVie, indicating close talent and strategic overlap.
• Sanofi: Sanofi operates a large immunology franchise (Dupixent) and has active business development in autoimmune and inflammation, making it a natural incumbent comparator and potential acquirer for Lakefront-style clinical assets.
• Bristol-Myers Squibb: BMS is a major oncology and immunology incumbent with established CAR-T franchises (Breyanzi, Abecma) that overlapped with Lakefront's discontinued cell therapy platform, and pursues small molecule immunology assets in adjacent indications.
• Roche: Roche is a global leader in oncology, immunology and biologics, with a broad bispecific antibody pipeline (e.g., mosunetuzumab, glofitamab) that overlaps with Lakefront's T-cell engager (gamgertamig) approach in autoimmune and hematologic indications.
• Johnson & Johnson: J&J operates a large immunology and oncology franchise (Stelara, Tremfya, Carvykti) that overlaps with Lakefront's autoimmune and cell therapy heritage, and regularly engages in major licensing and BD transactions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/GalapagosNV
• LinkedInlinkedin.com/company/lakefront-bio/about

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds14 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A8 records

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Galapagos